## Binding of autoantibodies to the acetylcholine receptor (AChR) plays a major role in the autoimmune disease Myasthenia gravis (MG). In this paper, we propose a structure model of a putative immunocomplex that gives rise to the reduction of functional AChR molecules during the course of MG. The mo
Compared structures of the free nicotinic acetylcholine receptor main immunogenic region (MIR) decapeptide and the antibody-bound [A76] MIR analogue: A molecular dynamics simulation from two-dimensional NMR data
โ Scribed by Piotr Orlewski; Michel Marraud; Manh-Thong Cung; Vassilios Tsikaris; Maria Sakarellos-Daitsiotis; Constantinos Sakarellos; Efstratia Vatzaki; Socrates J. Tzartos
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 1996
- Tongue
- English
- Weight
- 977 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0006-3525
No coin nor oath required. For personal study only.
โฆ Synopsis
Monoclonal antibodies against the main immunogenic region (MIR) of the muscle acetylcholine receptor (AChR) are capable of inducing experimental myasthenia gravis ( M G ) in animals. The epitope of these antibodies has been localized between residues 67 and 76 of the AChR a-subunit. The conformation in solution of the Torpedo californica MIR peptide and of its [A76]MIR analogue have been analyzed using molecular modeling based on nmr interproton distances and J-derived 4 dihedral angles. Molecular dynamics simulations including dimethylsulfoxide as explicit solvent have been carried out on the free MIR peptide. Calculation of the structure of the [A7']M1R analogue bound to an anti-MIR monoclonal antibody have been performed in the presence of water molecules. A tightly folded structure appears for both
Correspondence to: Mad-Thong Cung Contract grant sponsor: The Association FranGaise centre les Myopathies, the CNRS, BIOMED program of EU, and the HCM program of EU Contract grant number: CT93-1100 (BIOMED) and CT94-0547 (HCM) 0 1997 John Wiley & Sons, Inc. CCC 0006-3525/97/0504 19-14 419
peptides with a P-folded N-terminal NhX-P-A-D7' sequence of type I in the free state and type III in the mAb6-bound state. The C-terminal sequence is folded in two different ways according to the result in the free and bound state of the peptides: two overlapping PIP or p l a turns result in a short helical sequence in the free MIU peptide, whereas the bound analogue is folded by an uncommon hydrogen bond closing an 1 I membered cycle. This structural evolution is essentially the result of the reorientation of the hydrophobic side chains that are probably directly involved in peptide-antibody recognition.
๐ SIMILAR VOLUMES